Entrada Therapeutics, Inc. (TRDA) Stock Price & Analysis
Entrada Therapeutics, Inc. (TRDA) rose 5.47% to USD 7.52 as of September 9, 2026 at 13:27 UTC, according to Nexqual real-time market data.
TRDA last closed at USD 7.13; the session ranged USD 6.98–7.7 on volume of 513,931 shares. Market capitalization is $292.80M, with a 52-week range of USD 5.02–16.45 (NGM). Source: Nexqual, September 9, 2026 at 13:27 UTC.
Key Statistics (as of September 9, 2026 at 13:27 UTC)
| Price | USD 7.52 |
|---|---|
| Change | ▲ 5.47% (up) |
| Previous Close | USD 7.13 |
| Open | USD 7.02 |
| Day Range | USD 6.98 – 7.7 |
| 52-Week Range | USD 5.02 – 16.45 |
| Volume | 513,931 shares |
| Market Cap | $292.80M |
| Exchange | NGM |
Technical Analysis (TRDA)
Nexqual's technical model rates TRDA "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of September 9, 2026 at 13:27 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 58.79 (neutral) |
| vs SMA50 | Above (USD 7.06) |
| MACD | 0.06 (positive) |
Analyst Ratings (TRDA)
Wall Street analysts rate TRDA "Strong Buy" based on 4 analysts, with a mean price target of USD 19 (range USD 11–25), per Nexqual as of September 9, 2026 at 13:27 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 19 |
| High Target | USD 25 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (TRDA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.98 |
| Revenue Estimate | $5.26M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.01 vs est -1.04 ▲ beat |
| 2026-03-31 | USD -0.95 vs est -1.02 ▲ beat |
| 2025-12-31 | USD -0.94 vs est -1.16 ▲ beat |
| 2025-09-30 | USD -1.06 vs est -0.97 ▼ miss |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
Financials & Fundamentals (TRDA)
| Total Revenue | $4.69M |
|---|---|
| Revenue Growth (YoY) | -53.90% |
| Gross Margin | +0.00% |
| Operating Margin | -5007.02% |
| Profit Margin | +0.00% |
| ROE | -54.10% |
| Debt / Equity | 20.8 |
| Current Ratio | 10.89 |
| Total Cash | $223.00M |
| Total Debt | $48.54M |
| Free Cash Flow | $-77.67M |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
Financial Health Score (TRDA)
Nexqual rates Entrada Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of September 9, 2026 at 13:27 UTC.
| Growth | Critical — Revenue -88% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $223M cash vs $49M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$78M, burning cash |
| Efficiency | Critical — ROE -54%, ROA -29.2% |
Ownership (TRDA)
| Insider Ownership | +12.23% |
|---|---|
| Institutional Ownership | +82.73% |
| Shares Outstanding | 38.94M |
| Float | 19.84M |
| Short % of Float | +9.43% |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
Leadership (TRDA)
Entrada Therapeutics, Inc. is led by Dipal Doshi (age 49), CEO & Director, per Nexqual as of September 9, 2026 at 13:27 UTC.
| CEO & Director | Dipal Doshi (age 49) |
|---|---|
| President & COO | Nathan J. Dowden (age 54) |
| President of Research & Development | Natarajan Sethuraman (age 63) |
| CFO & Treasurer | Kory James Wentworth (age 46) |
| Senior Vice President of People | Kerry Robert M.S. |
Major Backers & Investors (TRDA)
Notable institutional backers of Entrada Therapeutics, Inc. include Baker Bros. Advisors, LP, 5AM Venture Management, LLC, Merck & Co., Inc., according to Nexqual as of September 9, 2026 at 13:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 13.03% |
| 5AM Venture Management, LLC | 10.42% |
| Merck & Co., Inc. | 4.47% |
| MPM Bioimpact LLC | 3.22% |
| TCG Crossover Management, LLC | 2.72% |
| Wellington Management | 2.45% |
| StepStone Group LP | 1.96% |
| Millennium Management | 1.96% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.69% |
| Vanguard Group | 6.81% |
Source: Nexqual, September 9, 2026 at 13:27 UTC.
From Entrada Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The cornerstone of our platform, our proprietary EEV peptides are based upon small cyclic peptides of approximately 10 amino acid residues or fewer.
- Intellectual Property We strive to protect our proprietary technology, inventions, improvements, platforms, program candidates, therapeutic candidates and components thereof, their methods of use and processes for their manufacture that we believe are important to our business, including by obtaining, maintaining, defending and enforcing patent and other intellectual property rights for the foregoing in the U.S. and in foreign jurisdictions.
- The portfolio includes patents covering certain embodiments of the EEV Platform that don't relate to our lead therapeutic candidates with granted patents in the U.S. (3), India, Japan, China, Hong Kong and Europe (including 37 European validation states).
- At the same time, however, as in our neuromuscular franchise, initial targets are selected based on well-understood biology, significant unmet need, translational clarity and the potential to differentiate based on our proprietary technologies and capabilities.
Partnerships
- In addition, our VX-670 partnership with Vertex Pharmaceuticals Incorporated ("Vertex") continues to progress, with dosing completion anticipated in mid-2026.
- Complementing the ongoing clinical progress of the DMD franchise is the myotonic dystrophy type 1 ("DM1") partnership with Vertex ("VX-670").
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TYRA | Tyra Biosciences, Inc. | USD 26.73 | ▲ 7.52% |
| JBIO | Jade Biosciences, Inc. | USD 19.45 | ▼ 2.02% |
| AURA | Aura Biosciences, Inc. | USD 7.36 | ▼ 0.14% |
| DSGN | Design Therapeutics, Inc. | USD 15.23 | ▲ 1.33% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 14.27 | ▼ 0.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 13:27 UTC. This page is informational and not investment advice.